` ADAP (Adaptimmune Therapeutics PLC) vs S&P 500 Comparison - Alpha Spread

ADAP
vs
S&P 500

Over the past 12 months, ADAP has underperformed S&P 500, delivering a return of -71% compared to the S&P 500's 9% growth.

Stocks Performance
ADAP vs S&P 500

Loading
ADAP
S&P 500
Add Stock

Performance Gap
ADAP vs S&P 500

Loading
ADAP
S&P 500
Difference
www.alphaspread.com

Performance By Year
ADAP vs S&P 500

Loading
ADAP
S&P 500
Add Stock

Competitors Performance
Adaptimmune Therapeutics PLC vs Peers

S&P 500
ADAP
ABBV
AMGN
GILD
VRTX
Add Stock

Adaptimmune Therapeutics PLC
Glance View

Market Cap
68.6m USD
Industry
Biotechnology

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

ADAP Intrinsic Value
1.3 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top